NIH Scientists Discover Safer, Highly Potent Opioid with Potential for Pain and Addiction Treatment
A newly discovered opioid compound by NIH researchers shows strong pain relief without typical addiction risks, marking a potential breakthrough in safer pain management therapies.
NIH | 06/04/2026 | By News Bureau
Phosplatin with NIH start patient dosing in stage 2 preliminary of PT-112
Phosplatin Therapeutics Inc., a clinical stage pharmaceutical company, announced the first patient has been treated in a phase 2 clinical trial of the company's lead therapeutic candidate, PT-112, in patients with recurrent thymic epithelial tumours (TETs), specifically thymoma and thymic carcinoma.
NIH | 15/04/2022 | By Sudeep Soparkar | 237
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy